Therapeutic transformation for diabetic kidney disease.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 33509348.
- Also identified by DOI 10.1016/j.kint.2020.10.003.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Risks of kidney failure and heart failure are markedly reduced by inhibition of the sodium glucose cotransporter 2 (SGLT2) in patients with diabetic kidney disease. In a post hoc analysis of the Study of Diabetic Nephropathy with Atrasentan (SONAR) trial, drop-in SGLT2 inhibitor usage during the atrasentan enrichment period led to greater reduction in albuminuria compared with atrasentan alone. These data support the hypothesis of greater longer-term kidney protection by combination SGLT2 inhibition and endothelin A receptor antagonism that could be tested in future clinical trials.
Medical subject headings
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Heart Failure
- Sodium-Glucose Transporter 2 Inhibitors